Rosalba Mansi

12PUBLICATIONS
21CO-AUTHORS
Characterisation of biological macromoleculesCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 01, 2025
Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution.

Rosalba Mansi, Natalie Bertarelli, Luigi Del Pozzo

|Jan 09, 2025
Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4.

Raghuvir H Gaonkar, Thibaud Bailly, Jacopo Millul

|May 06, 2024
Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy.

Luigi Aloj, Rosalba Mansi, Stefania De Luca

|May 27, 2023
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.

Berthold A Nock, Panagiotis Kanellopoulos, Lieke Joosten

|Sep 23, 2022
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours.

Pascale Plas, Lorenzo Limana, Denis Carré

|Mar 10, 2022
Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.

Melpomeni Fani, Rosalba Mansi, Guillaume P Nicolas

Pageof 2

Frequent Collaborators

5 joint publications

Melpomeni Fani

2 joint publications

Raghuvir Haridas Gaonkar

2 joint publications

Berthold A Nock

2 joint publications

Theodosia Maina